BOSTON, MA — August 26, 2025 — Leads & Copy — Life Biosciences (“Life Bio”) announced new preclinical data at the 12th Aging Research and Drug Discovery (ARDD) Meeting, highlighting the therapeutic impact of its Partial Epigenetic Reprogramming (PER) platform, designed to reverse optic neuropathies and metabolic dysfunction-associated steatohepatitis (MASH).
The PER platform partially reprograms the epigenome of aged and injured cells using three of the four Yamanaka factors [Oct4, Sox2, Klf4 (OSK)], targeting a root cause of aging at the epigenetic level.
ER-300 improved liver scores in a preclinical mouse model of MASH, while ER-100 restored methylation patterns and neuronal regeneration in a nonhuman primate model of NAION.
“We are encouraged by the potential of ER-300 to improve key liver scores,” said Jerry McLaughlin, CEO of Life Bio. Sharon Rosenzweig-Lipson, Ph.D., CSO, added, “These results bring us closer to pioneering a new class of epigenetic therapies.”
Key presentation highlights include ER-300’s significant improvement in liver scores in a MASH mouse model and ER-100’s restoration of methylation patterns in a NAION primate model.
ER-100 is slated to enter human trials in Q1 2026 for two optic neuropathies. Life Bio is expanding its pipeline to address other age-related diseases.
Contact: Jason Braco, PhD, LifeSci Communications, lifebio@lifescicomms.com
Source: Life Biosciences
